Systemic adjuvant therapy for patients with high-risk melanoma

Archives of Dermatology

Volumn 143, Issue 6, 2007, Pages 779-782

  Tsai, Kenneth Y ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CARMUSTINE; DACARBAZINE; DACTINOMYCIN; HYDROXYUREA; INTERFERON; LOMUSTINE; METHOTREXATE; PROCARBAZINE; RUFOCROMOMYCIN; THIOTEPA; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; CANCER RISK; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; MELANOMA; NOTE; PRIORITY JOURNAL; RECURRENT CANCER; UNSPECIFIED SIDE EFFECT;

EID: 34250747419     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.6.779     Document Type: Note

References (17)

1. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13:2776-2783.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
3. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.
4. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
5. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48:2787-2792.
6. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677.
7. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? a meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29:241-252.
8. Pirard D, Heenen M, Melot C, Vereecken P. Interferon alpha as adjuvant post-surgical treatment of melanoma: a meta-analysis. Dermatology. 2004;208:43-48.
9. André T, de Gramont A; Study Group of Clinical Research in Radiotherapies Oncology, Oncology Multidiciplinary Research Group. An overview of adjuvant systemic chemotherapy for colon cancer. Clin Colorectal Cancer. 2004;4(suppl 1):S22-S28.
10. Sondak VK, Sosman JA, Unger JM, et al. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine: final analysis of SWOG-9035 [abstract]. J Clin Oncol. 2004;22:7501.
11. Sosman JA, Unger JM, Liu PY, et al. HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from Melacine vaccine: an updated analysis of SWOG 9035 [abstract]. Proc Am Soc Clin Oncol. 2002;21:340a.
12. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20:2058-2066.
13. Sosman JA, Unger JM, Liu PY, et al; Southwest Oncology Group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol. 2002;20:2067-2075.
14. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307:913-916.
15. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14:2666-2673.
16. Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002;20:1311-1318.
17. Morton DL, Thompson JF, Cochran AJ, et al; MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.